Senior Consultant, Division of Radiation Oncology, National Cancer Centre Singapore, Singapore; Assistant Professor, Duke-NUS Medical School
Dr Melvin Chua is a clinician-scientist, and Principal Investigator of the Precision Radiation Oncology Programme, Division of Radiation Oncology, with a track record of more than 13,000,000 SGD of competitive grant funding (as primary and joint applicant). He is also supported by the NMRC Clinician-Scientist Award. He currently leads his research focusing on precision medicine using prognostic and predictive biomarkers, and experimental therapeutics in the management of prostate and nasopharynx cancers. In particular, his group is interested in using modern “omics” approaches to interrogate the molecular underpinnings of radioresistance of these tumours; layering these datasets with validated prognostic clinical tools the group has developed (www.PRANCIS.Medlever.com) to improve clinical risk stratification and precision treatment of patients. Separately, the programme also recently joined the PRACTICAL Prostate Cancer Genomics Consortia, a global consortium that aims to characterise prostate cancer risk susceptibility genes in 200,000 men across different racial ancestries.
Dr Chua is also currently involved in a National Research Foundation-funded 5-year clinical research programme (as the co-Principal Investigator) to investigate novel mechanisms of proton beam therapy (PBT) targeting of tumours; the programme themes encompass characterising exclusive genomic and epigenomic alterations induced by PBT; differential immune responses between PBT and conventional photon irradiation; testing novel drug and nanoparticle conjugate combinations with PBT; and developing novel imaging tools to survey for treatment responses.